Management of open‐angle glaucoma by primary eye‐care practitioners: toward a personalised medicine approach

References

• Tham YC, Li X, Wong TY et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta‐analysis. Ophthalmology 2014; 121: 2081–2090.
   Web of Science ®Google Scholar
• Heijl A, Bengtsson B, Oskarsdottir SE. Prevalence and severity of undetected manifest glaucoma: results from the early manifest glaucoma trial screening. Ophthalmology 2013; 120: 1541–1545.
   Web of Science ®Google Scholar
• Mitchell P, Smith W, Attebo K et al. Prevalence of open‐angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 1661–1669.
   Web of Science ®Google Scholar
• Chua J, Baskaran M, Ong PG et al. Prevalence, risk factors, and visual features of undiagnosed Glaucoma: the Singapore epidemiology of eye diseases Study. JAMA Ophthalmol 2015; 133: 938–946.
   Web of Science ®Google Scholar
• Varma R, Ying‐lai M, Francis BA et al. Prevalence of open‐angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino eye Study. Ophthalmology 2004; 111: 1439–1448.
   Web of Science ®Google Scholar
• Dandona L, Dandona R, Srinivas M et al. Open‐angle glaucoma in an urban population in southern India: the Andhra Pradesh eye disease study. Ophthalmology 2000; 107: 1702–1709.
   Web of Science ®Google Scholar
• Ang GS, Eke T. Lifetime visual prognosis for patients with primary open‐angle glaucoma. Eye (Lond) 2007; 21: 604–608.
   Web of Science ®Google Scholar
• Rahman MQ, Beard SM, Discombe R et al. Direct healthcare costs of glaucoma treatment. Br J Ophthalmol 2013; 97: 720–724.
   Web of Science ®Google Scholar
• Casson RJ, Chidlow G, Wood JP et al. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol 2012; 40: 341–349.
   Web of Science ®Google Scholar
• Shah SM, Choo C, Odden J et al. Provider agreement in the assessment of Glaucoma progression within a team model. J Glaucoma 2018; 27: 691–698.
   Web of Science ®Google Scholar
• Marks JR, Harding AK, Harper RA et al. Agreement between specially trained and accredited optometrists and glaucoma specialist consultant ophthalmologists in their management of glaucoma patients. Eye (Lond) 2012; 26: 853–861.
   Web of Science ®Google Scholar
• Lin AP, Katz LJ, Spaeth GL et al. Agreement of visual field interpretation among glaucoma specialists and comprehensive ophthalmologists: comparison of time and methods. Br J Ophthalmol 2011; 95: 828–831.
   Web of Science ®Google Scholar
• Banes MJ, Culham LE, Bunce C et al. Agreement between optometrists and ophthalmologists on clinical management decisions for patients with glaucoma. Br J Ophthalmol 2006; 90: 579–585.
   Web of Science ®Google Scholar
• Reus NJ, Lemij HG, Garway‐heath DF et al. Clinical assessment of stereoscopic optic disc photographs for glaucoma: the European optic disc assessment trial. Ophthalmology 2010; 117: 717–723.
   Web of Science ®Google Scholar
• van der Schoot J, Reus NJ, Garway‐heath DF et al. Accuracy of matching optic discs with visual fields: the European structure and function assessment trial (ESAFAT). Ophthalmology 2013; 120: 2470–2475.
   Web of Science ®Google Scholar
• Phu J, Wang H, Khou V et al. Remote grading of the anterior chamber angle using Goniophotographs and optical coherence tomography: implications for telemedicine or virtual clinics. Transl Vis Sci Technol 2019; 8: 16.
   Web of Science ®Google Scholar
• Phu J, Wang H, Khuu SK et al. Anterior chamber angle evaluation using Gonioscopy: consistency and agreement between optometrists and ophthalmologists. Optom Vis Sci 2019; 96: 751–760.
   Web of Science ®Google Scholar
• Founti P, Coleman AL, Wilson MR et al. Overdiagnosis of open‐angle glaucoma in the general population: the Thessaloniki eye Study. Acta Ophthalmol 2018; 96: e859–e864.
   Web of Science ®Google Scholar
• Nayak BK, Maskati QB, Parikh R. The unique problem of glaucoma: under‐diagnosis and over‐treatment. Indian J Ophthalmol 2011; 59: S1–S2.
   Web of Science ®Google Scholar
• Heijl A, Bengtsson B, Hyman L et al. Natural history of open‐angle glaucoma. Ophthalmology 2009; 116: 2271–2276.
   Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open‐angle glaucoma. Arch Ophthalmol 2002; 120: 701–713.
   Google Scholar
• Huang J, Hennessy MP, Kalloniatis M et al. Implementing collaborative care for glaucoma patients and suspects in Australia. Clin Exp Ophthalmol 2018; 46: 826–828.
   Web of Science ®Google Scholar
• Jamous KF, Kalloniatis M, Hennessy MP et al. Clinical model assisting with the collaborative care of glaucoma patients and suspects. Clin Exp Ophthalmol 2015; 43: 308–319.
   Web of Science ®Google Scholar
• Phu J, Hennessy MP, Spargo M et al. A collaborative care pathway for patients with suspected angle closure glaucoma spectrum disease. Clin Exp Optom 2020; 103: 212–219.
   Web of Science ®Google Scholar
• National Health and Medical Research Council. Guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma. In. Internet: Commonwealth of Australia, 2010.
   Google Scholar
• Pillunat KR, Spoerl E, Elfes G et al. Preoperative intraocular pressure as a predictor of selective laser trabeculoplasty efficacy. Acta Ophthalmol 2016; 94: 692–696.
   Web of Science ®Google Scholar
• Konstas AG, Kahook MY, Araie M et al. Diurnal and 24‐h intraocular pressures in glaucoma: monitoring strategies and impact on prognosis and treatment. Adv Ther 2018; 35: 1775–1804.
   Web of Science ®Google Scholar
• Huang J, Katalinic P, Kalloniatis M et al. Diurnal intraocular pressure fluctuations with self‐tonometry in glaucoma patients and suspects: a clinical trial. Optom Vis Sci 2018; 95: 88–95.
   Web of Science ®Google Scholar
• Huang J, Phu J, Kalloniatis M et al. Determining significant elevation of intraocular pressure using self‐tonometry. Optom Vis Sci 2020; 97: 86–93.
   Web of Science ®Google Scholar
• Susanna R Jr, Clement C, Goldberg I et al. Applications of the water drinking test in glaucoma management. Clin Exp Ophthalmol 2017; 45: 625–631.
   Web of Science ®Google Scholar
• Morgan WH, Balaratnasingam C, Lind CR et al. Cerebrospinal fluid pressure and the eye. Br J Ophthalmol 2016; 100: 71–77.
   Web of Science ®Google Scholar
• Jonas JB, Ritch R, Panda‐jonas S. Cerebrospinal fluid pressure in the pathogenesis of glaucoma. Prog Brain Res 2015; 221: 33–47.
   Web of Science ®Google Scholar
• Friedman DS, He M. Anterior chamber angle assessment techniques. Surv Ophthalmol 2008; 53: 250–273.
   Web of Science ®Google Scholar
• Smith SD, Singh K, Lin SC et al. Evaluation of the anterior chamber angle in glaucoma: a report by the american academy of ophthalmology. Ophthalmology 2013; 120: 1985–1997.
   Web of Science ®Google Scholar
• Varma DK, Kletke SN, Rai AS et al. Proportion of undetected narrow angles or angle closure in cataract surgery referrals. Can J Ophthalmol 2017; 52: 366–372.
   Web of Science ®Google Scholar
• Varma DK, Simpson SM, Rai AS et al. Undetected angle closure in patients with a diagnosis of open‐angle glaucoma. Can J Ophthalmol 2017; 52: 373–378.
   Web of Science ®Google Scholar
• Iwanejko M, Turno‐krecicka A, Tomczyk‐socha M et al. Evaluation of the anterior chamber angle in pseudoexfoliation syndrome. Adv Clin Exp Med 2017; 26: 795–801.
   Web of Science ®Google Scholar
• Shuba L, Nicolela MT, Rafuse PE. Correlation of capsular pseudoexfoliation material and iridocorneal angle pigment with the severity of pseudoexfoliation glaucoma. J Glaucoma 2007; 16: 94–97.
   Web of Science ®Google Scholar
• Salmon JF, Mermoud A, Ivey A et al. The detection of post‐traumatic angle recession by gonioscopy in a population‐based glaucoma survey. Ophthalmology 1994; 101: 1844–1850.
   Web of Science ®Google Scholar
• Sihota R, Kumar S, Gupta V et al. Early predictors of traumatic glaucoma after closed globe injury: trabecular pigmentation, widened angle recess, and higher baseline intraocular pressure. Arch Ophthalmol 2008; 126: 921–926.
   Google Scholar
• Richter CU, Richardson TM, Grant WM. Pigmentary dispersion syndrome and pigmentary glaucoma. A prospective study of the natural history. Arch Ophthalmol 1986; 104: 211–215.
   Google Scholar
• Wang C, Dang Y, Loewen RT et al. Impact of pigment dispersion on trabecular meshwork cells. Graefes Arch Clin Exp Ophthalmol 2019; 257: 1217–1230.
   Web of Science ®Google Scholar
• Niyadurupola N, Broadway DC. Pigment dispersion syndrome and pigmentary glaucoma–a major review. Clin Exp Ophthalmol 2008; 36: 868–882.
   Web of Science ®Google Scholar
• Matos AG, Asrani SG, Paula JS. Feasibility of laser trabeculoplasty in angle closure glaucoma: a review of favourable histopathological findings in narrow angles. Clin Exp Ophthalmol 2017; 45: 632–639.
   Web of Science ®Google Scholar
• Phu J, Khuu SK, Yapp M et al. The value of visual field testing in the era of advanced imaging: clinical and psychophysical perspectives. Clin Exp Optom 2017; 100: 313–332.
   Web of Science ®Google Scholar
• Jampel HD, Singh K, Lin SC et al. Assessment of visual function in glaucoma: a report by the American Academy of ophthalmology. Ophthalmology 2011; 118: 986–1002.
   Web of Science ®Google Scholar
• De moraes CG, Hood DC, Thenappan A et al. 24–2 Visual fields miss central defects shown on 10–2 tests in Glaucoma suspects, ocular hypertensives, and early Glaucoma. Ophthalmology 2017; 124: 1449–1456.
   Web of Science ®Google Scholar
• Wu Z, Medeiros FA, Weinreb RN et al. Performance of the 10–2 and 24–2 visual field tests for detecting central visual field abnormalities in Glaucoma. Am J Ophthalmol 2018; 196: 10–17.
   Web of Science ®Google Scholar
• Sullivan‐mee M, Karin tran MT, Pensyl D et al. Prevalence, features, and severity of glaucomatous visual field loss measured with the 10–2 achromatic threshold visual field test. Am J Ophthalmol 2016; 168: 40–51.
   Web of Science ®Google Scholar
• White A, Goldberg I, Australian and New Zealand Glaucoma Interest Group and the Royal Australian and New Zealand College of Ophthalmologists. Guidelines for the collaborative care of glaucoma patients and suspects by ophthalmologists and optometrists in Australia. Clin Exp Ophthalmol 2014; 42: 107–117.
   Web of Science ®Google Scholar
• Brusini P, Johnson CA. Staging functional damage in glaucoma: review of different classification methods. Surv Ophthalmol 2007; 52: 156–179.
   Web of Science ®Google Scholar
• Phu J, Khuu SK, Agar A et al. Clinical evaluation of Swedish interactive thresholding algorithm‐faster compared with Swedish interactive thresholding algorithm‐standard in Normal subjects, Glaucoma suspects, and patients with Glaucoma. Am J Ophthalmol 2019; 208: 251–264.
   Web of Science ®Google Scholar
• Heijl A, Patella VM, Chong LX et al. A new SITA Perimetric threshold testing algorithm: construction and a multicenter clinical study. Am J Ophthalmol 2019; 198: 154–165.
   Web of Science ®Google Scholar
• Crabb DP, Garway‐heath DF. Intervals between visual field tests when monitoring the glaucomatous patient: wait‐and‐see approach. Invest Ophthalmol Vis Sci 2012; 53: 2770–2776.
   Web of Science ®Google Scholar
• Schulz AM, Graham EC, You Y et al. Performance of iPad‐based threshold perimetry in glaucoma and controls. Clin Exp Ophthalmol 2018; 46: 346–355.
   Web of Science ®Google Scholar
• Jones PR, Smith ND, Bi W et al. Portable Perimetry using eye‐tracking on a tablet computer‐a feasibility assessment. Transl Vis Sci Technol 2019; 8: 17.
   Web of Science ®Google Scholar
• Matsumoto C, Yamao S, Nomoto H et al. Visual field testing with head‐mounted perimeter 'imo'. PLoS One 2016; 11: e0161974.
   Web of Science ®Google Scholar
• Phu J, Khuu SK, Zangerl B et al. A comparison of Goldmann III, V and spatially equated test stimuli in visual field testing: the importance of complete and partial spatial summation. Ophthalmic Physiol Opt 2017; 37: 160–176.
   Web of Science ®Google Scholar
• Tong J, Phu J, Khuu SK et al. Development of a spatial model of age‐related change in the macular ganglion cell layer to predict function from structural changes. Am J Ophthalmol 2019; 208: 166–177.
   Web of Science ®Google Scholar
• Kalloniatis M, Khuu SK. Equating spatial summation in visual field testing reveals greater loss in optic nerve disease. Ophthalmic Physiol Opt 2016; 36: 439–452.
   Web of Science ®Google Scholar
• Ballae ganeshrao S, Turpin A, Denniss J et al. Enhancing structure‐function correlations in Glaucoma with customized spatial mapping. Ophthalmology 2015; 122: 1695–1705.
   Web of Science ®Google Scholar
• Chong LX, Mckendrick AM, Ganeshrao SB et al. Customized, automated stimulus location choice for assessment of visual field defects. Invest Ophthalmol Vis Sci 2014; 55: 3265–3274.
   Web of Science ®Google Scholar
• Gordon MO, Kass MA. the ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol 1999; 117: 573–583.
   Google Scholar
• Leske MC, Heijl A, Hyman L et al. Early manifest Glaucoma trial: design and baseline data. Ophthalmology 1999; 106: 2144–2153.
   Web of Science ®Google Scholar
• Parrish RK 2nd, Feuer WJ, Schiffman JC et al. Five‐year follow‐up optic disc findings of the collaborative initial Glaucoma Treatment Study. Am J Ophthalmol 2009; 147: 717–724 e711.
   Web of Science ®Google Scholar
• Medeiros FA. Biomarkers and surrogate endpoints: lessons learned from Glaucoma. Invest Ophthalmol Vis Sci 2017; 58: BIO20–BIO26.
   Web of Science ®Google Scholar
• Ly A, Phu J, Katalinic P et al. An evidence‐based approach to the routine use of optical coherence tomography. Clin Exp Optom 2019; 102: 242–259.
   Web of Science ®Google Scholar
• Kansal V, Armstrong JJ, Pintwala R et al. Optical coherence tomography for glaucoma diagnosis: an evidence based meta‐analysis. PLoS One 2018; 13: e0190621.
   Web of Science ®Google Scholar
• Mwanza JC, Warren JL, Budenz DL. Utility of combining spectral domain optical coherence tomography structural parameters for the diagnosis of early Glaucoma: a mini‐review. Eye Vis (Lond) 2018; 5: 9.
   Google Scholar
• Pomorska M, Krzyzanowska‐berkowska P, Misiuk‐hojlo M et al. Application of optical coherence tomography in glaucoma suspect eyes. Clin Exp Optom 2012; 95: 78–88.
   Web of Science ®Google Scholar
• Pinero DP, Alcon N. Corneal biomechanics: a review. Clin Exp Optom 2015; 98: 107–116.
   Web of Science ®Google Scholar
• Sng CC, Ang M, Barton K. Central corneal thickness in glaucoma. Curr Opin Ophthalmol 2017; 28: 120–126.
   Web of Science ®Google Scholar
• Detorakis ET, Pallikaris IG. Ocular rigidity: biomechanical role, in vivo measurements and clinical significance. Clin Exp Ophthalmol 2013; 41: 73–81.
   Web of Science ®Google Scholar
• Saunders LJ, Russell RA, Crabb DP. Practical landmarks for visual field disability in glaucoma. Br J Ophthalmol 2012; 96: 1185–1189.
   Web of Science ®Google Scholar
• Caprioli J. The importance of rates in glaucoma. Am J Ophthalmol 2008; 145: 191–192.
   Web of Science ®Google Scholar
• Collaborative Normal‐Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal‐tension glaucoma. Am J Ophthalmol 1998; 126: 498–505.
   Web of Science ®Google Scholar
• Sakata R, Yoshitomi T, Iwase A et al. Factors associated with progression of Japanese open‐angle Glaucoma with lower Normal intraocular pressure. Ophthalmology 2019; 126: 1107–1116.
   Web of Science ®Google Scholar
• Sawada A, Manabe Y, Yamamoto T et al. Long‐term clinical course of normotensive preperimetric glaucoma. Br J Ophthalmol 2017; 101: 1649–1653.
   Web of Science ®Google Scholar
• Garway‐heath DF, Crabb DP, Bunce C et al. Latanoprost for open‐angle glaucoma (UKGTS): a randomised, multicentre, placebo‐controlled trial. Lancet 2015; 385: 1295–1304.
   Google Scholar
• Kass MA, Gordon MO, Gao F et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 2010; 128: 276–287.
   Google Scholar
• Ocular Hypertension Treatment Study G, European Glaucoma Prevention Study G, Gordon MO et al. Validated prediction model for the development of primary open‐angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007; 114: 10–19.
   Web of Science ®Google Scholar
• Oliver JE, Hattenhauer MG, Herman D et al. Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol 2002; 133: 764–772.
   Web of Science ®Google Scholar
• Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open‐angle glaucoma blindness. Acta Ophthalmol 2014; 92: 421–425.
   Web of Science ®Google Scholar
• Chen PP. Blindness in patients with treated open‐angle glaucoma. Ophthalmology 2003; 110: 726–733.
   Web of Science ®Google Scholar
• Forsman E, Kivela T, Vesti E. Lifetime visual disability in open‐angle glaucoma and ocular hypertension. J Glaucoma 2007; 16: 313–319.
   Web of Science ®Google Scholar
• Kooner KS, Albdoor M, Cho BJ et al. Risk factors for progression to blindness in high tension primary open angle glaucoma: comparison of blind and nonblind subjects. Clin Ophthalmol 2008; 2: 757–762.
   Google Scholar
• Vianna JR, Danthurebandara VM, Sharpe GP et al. Importance of normal aging in estimating the rate of glaucomatous neuroretinal rim and retinal nerve fiber layer loss. Ophthalmology 2015; 122: 2392–2398.
   Web of Science ®Google Scholar
• Yoshioka N, Zangerl B, Phu J et al. Consistency of structure‐function correlation between spatially scaled visual field stimuli and in vivo OCT ganglion cell counts. Invest Ophthalmol Vis Sci 2018; 59: 1693–1703.
   Web of Science ®Google Scholar
• Phu J, Khuu SK, Nivison‐smith L et al. Pattern recognition analysis reveals unique contrast sensitivity Isocontours using static perimetry thresholds across the visual field. Invest Ophthalmol Vis Sci 2017; 58: 4863–4876.
   Web of Science ®Google Scholar
• Anderson AJ, Asokan R, Murata H et al. Detecting glaucomatous progression with infrequent visual field testing. Ophthalmic Physiol Opt 2018; 38: 174–182.
   Web of Science ®Google Scholar
• Mohindroo C, Ichhpujani P, Kumar S. Current imaging modalities for assessing Ocular blood flow in Glaucoma. J Curr Glaucoma Pract 2016; 10: 104–112.
   Google Scholar
• Mackey DA, Hewitt AW. Genome‐wide association study success in ophthalmology. Curr Opin Ophthalmol 2014; 25: 386–393.
   Web of Science ®Google Scholar
• Phu J, Khuu SK, Agar A et al. Visualising the consistency of clinical characteristics that distinguish healthy, suspect and manifest glaucoma patients. Ophthalmology Glaucoma 2020. https://doi.org/10.1016/j.ogla.2020.04.009.
   Google Scholar
• Samples JR, Singh K, Lin SC et al. Laser trabeculoplasty for open‐angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology 2011; 118: 2296–2302.
   Web of Science ®Google Scholar
• Kalouda P, Keskini C, Anastasopoulos E et al. Achievements and limits of current medical therapy of glaucoma. Dev Ophthalmol 2017; 59: 1–14.
   Google Scholar
• Li T, Lindsley K, Rouse B et al. Comparative effectiveness of first‐line medications for primary open‐angle glaucoma: a systematic review and network meta‐analysis. Ophthalmology 2016; 123: 129–140.
   Web of Science ®Google Scholar
• Tanna AP, Lin AB. Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr Opin Ophthalmol 2015; 26: 116–120.
   Web of Science ®Google Scholar
• Garg A, Gazzard G. Selective laser trabeculoplasty: past, present, and future. Eye (Lond) 2018; 32: 863–876.
   Web of Science ®Google Scholar
• Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand‐alone surgery for glaucoma. Clin Exp Ophthalmol 2017; 45: 393–400.
   Web of Science ®Google Scholar
• Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998; 67: 179–191.
   Web of Science ®Google Scholar
• Yamada H, Yoneda M, Gosho M et al. Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases. BMC Ophthalmol 2016; 16: 26.
   Web of Science ®Google Scholar
• Kim JW, Lindsey JD, Wang N et al. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 2001; 42: 1514–1521.
   Web of Science ®Google Scholar
• Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother 2012; 13: 723–745.
   Google Scholar
• Konstas AG, Katsanos A, Quaranta L et al. Twenty‐four hour efficacy of glaucoma medications. Prog Brain Res 2015; 221: 297–318.
   Web of Science ®Google Scholar
• Ong LB, Liza‐sharmini AT, Chieng LL et al. The efficacy of timolol in gel‐forming solution after morning or evening dosing in Asian glaucomatous patients. J Ocul Pharmacol Ther 2005; 21: 388–394.
   Web of Science ®Google Scholar
• Schenker H, Maloney S, Liss C et al. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel‐forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open‐angle glaucoma. Clin Ther 1999; 21: 138–147.
   Web of Science ®Google Scholar
• Quaranta L, Gandolfo F, Turano R et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006; 47: 2917–2923.
   Web of Science ®Google Scholar
• Rennie G, Wilkinson A, White A et al. Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta‐analysis. Curr Med Res Opin 2019; 35: 1421–1431.
   Web of Science ®Google Scholar
• van der Valk R, Webers CA, Schouten JS et al. Intraocular pressure‐lowering effects of all commonly used glaucoma drugs: a meta‐analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177–1185.
   Web of Science ®Google Scholar
• Toris CB, Gleason ML, Camras CB et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514–1517.
   Google Scholar
• Oh DJ, Chen JL, Vajaranant TS et al. Brimonidine tartrate for the treatment of glaucoma. Expert Opin Pharmacother 2019; 20: 115–122.
   Web of Science ®Google Scholar
• De moraes CG, Liebmann JM, Greenfield DS et al. Risk factors for visual field progression in the low‐pressure glaucoma treatment study. Am J Ophthalmol 2012; 154: 702–711.
   Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low‐pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151: 671–681.
   Web of Science ®Google Scholar
• Semba K, Namekata K, Kimura A et al. Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma. Cell Death Dis 2014; 5: e1341.
   Web of Science ®Google Scholar
• Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2017; 1: CD006539.
   Google Scholar
• Schuman JS. Effects of systemic beta‐blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study groups 1 and 2. Ophthalmology 2000; 107: 1171–1177.
   Web of Science ®Google Scholar
• Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol 2002; 37: 21–26.
   Web of Science ®Google Scholar
• Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open‐angle glaucoma and ocular hypertension. Drugs Aging 1998; 12: 225–241.
   Web of Science ®Google Scholar
• Arthur S, Cantor LB. Update on the role of alpha‐agonists in glaucoma management. Exp Eye Res 2011; 93: 271–283.
   Web of Science ®Google Scholar
• Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma 2009; 18: 395–398.
   Web of Science ®Google Scholar
• Lin SL, Liang SS. Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution. J Ocul Pharmacol Ther 1995; 11: 267–278.
   Web of Science ®Google Scholar
• Butler P, Mannschreck M, Lin S et al. Clinical experience with the long‐term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995; 113: 293–296.
   Google Scholar
• Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open‐angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol 2000; 44: S155–S162.
   Web of Science ®Google Scholar
• Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000; 44: S141–S145.
   Web of Science ®Google Scholar
• Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open‐angle glaucoma and ocular hypertension. Drugs Aging 2003; 20: 919–947.
   Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Invernizzi T et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 41: 2566–2573.
   Web of Science ®Google Scholar
• Guedes GB, Karan A, Mayer HR et al. Evaluation of adverse events in self‐reported sulfa‐allergic patients using topical carbonic anhydrase inhibitors. J Ocul Pharmacol Ther 2013; 29: 456–461.
   Web of Science ®Google Scholar
• Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000; 22: 1204–1212.
   Web of Science ®Google Scholar
• Noecker R, Miller KV. Benzalkonium chloride in glaucoma medications. Ocul Surf 2011; 9: 159–162.
   Web of Science ®Google Scholar
• Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000; 22: 167–208.
   Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, Mccluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012; 153: 1 9 e2.
   Google Scholar
• Stringham J, Ashkenazy N, Galor A et al. Barriers to glaucoma medication compliance among veterans: dry eye symptoms and anxiety disorders. Eye Contact Lens 2018; 44: 50–54.
   Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma 2013; 22: 730–735.
   Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P et al. Ocular symptoms and signs with preserved and preservative‐free glaucoma medications. Eur J Ophthalmol 2007; 17: 341–349.
   Web of Science ®Google Scholar
• Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in‐life utilization. J Glaucoma 2001; 10: 483–486.
   Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride‐preserved, polyquad‐preserved, and sofZia‐preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010; 27: 837–845.
   Web of Science ®Google Scholar
• Yalvac IS, Gedikoglu G, Karagoz Y et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand 1995; 73: 246–248.
   Google Scholar
• Labbe A, Terry O, Brasnu E et al. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea 2012; 31: 994–999.
   Web of Science ®Google Scholar
• Martone G, Frezzotti P, Tosi GM et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009; 147: 725–735 e721.
   Web of Science ®Google Scholar
• De saint JM, Brignole F, Bringuier AF et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999; 40: 619–630.
   Web of Science ®Google Scholar
• Broadway D, Hitchings R, Grierson I. Topical antiglaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery. J Glaucoma 1995; 4: 136.
   Google Scholar
• Chang C, Zhang AQ, Kagan DB et al. Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative‐free tafluprost. Clin Exp Ophthalmol 2015; 43: 164–172.
   Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride‐ or polyquad‐preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 2011; 17: 1806–1813.
   Web of Science ®Google Scholar
• Chetoni P, Burgalassi S, Monti D et al. Ocular toxicity of some corneal penetration enhancers evaluated by electrophysiology measurements on isolated rabbit corneas. Toxicol In Vitro 2003; 17: 497–504.
   Web of Science ®Google Scholar
• Green K, Tonjum AM. The effect of benzalkonium chloride on the electropotential of the rabbit cornea. Acta Ophthalmol (Copenh) 1975; 53: 348–357.
   Web of Science ®Google Scholar
• de Jong C, Stolwijk T, Kuppens E et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol 1994; 232: 221–224.
   Web of Science ®Google Scholar
• Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative‐free tafluprost. Ophthalmic Res 2009; 41: 118–122.
   Web of Science ®Google Scholar
• Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative‐free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf) 2008; 242: 7–13.
   Google Scholar
• Hamacher T, Airaksinen J, Saarela V et al. Efficacy and safety levels of preserved and preservative‐free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 2008; 242: 14–19.
   Google Scholar
• Day DG, Walters TR, Schwartz GF et al. Bimatoprost 0.03% preservative‐free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12‐week, randomised, double‐masked trial. Br J Ophthalmol 2013; 97: 989–993.
   Web of Science ®Google Scholar
• Rouland JF, Traverso CE, Stalmans I et al. Efficacy and safety of preservative‐free latanoprost eyedrops, compared with BAK‐preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol 2013; 97: 196–200.
   Web of Science ®Google Scholar
• Munoz negrete FJ, Lemij HG, Erb C. Switching to preservative‐free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol 2017; 11: 557–566.
   Google Scholar
• Uusitalo H, Chen E, Pfeiffer N et al. Switching from a preserved to a preservative‐free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010; 88: 329–336.
   Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY et al. TFOS DEWS II epidemiology report. Ocul Surf 2017; 15: 334–365.
   Web of Science ®Google Scholar
• Tachkov K, Vassilev A, Kostova S. Modeling the pharmacotherapy cost and outcomes of primary open‐angle Glaucoma with dry eye. Front Public Health 2019; 7: 363.
   Web of Science ®Google Scholar
• Thygesen J. Glaucoma therapy: preservative‐free for all? Clin Ophthalmol 2018; 12: 707–717.
   Web of Science ®Google Scholar
• Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol 2018; 102: 1497–1503.
   Google Scholar
• Kucukevcilioglu M, Bayer A, Uysal Y et al. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol 2014; 42: 126–131.
   Web of Science ®Google Scholar
• Tang W, Zhang F, Liu K et al. Efficacy and safety of prostaglandin analogues in primary open‐angle glaucoma or ocular hypertension patients: a meta‐analysis. Medicine (Baltimore) 2019; 98: e16597.
   Web of Science ®Google Scholar
• Stjernschantz JW, Albert DM, Hu DN et al. Mechanism and clinical significance of prostaglandin‐induced iris pigmentation. Surv Ophthalmol 2002; 47: S162–S175.
   Web of Science ®Google Scholar
• Kim DH, Addis VM, Pan W et al. Comparative effectiveness of generic Latanoprost versus branded prostaglandin analogs for primary open angle Glaucoma. Ophthalmic Epidemiol 2019; 26: 63–71.
   Web of Science ®Google Scholar
• Ta kim D, Daigle P, Carbonneau M. Randomized crossover trial comparing effectiveness and tolerability of generic and brand‐name travoprost. Can J Ophthalmol 2019; 54: 223–228.
   Web of Science ®Google Scholar
• Narayanaswamy A, Neog A, Baskaran M et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 2007; 55: 127–131.
   Google Scholar
• Kahook MY, Fechtner RD, Katz LJ et al. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography‐tandem mass spectrometry. Curr Eye Res 2012; 37: 101–108.
   Web of Science ®Google Scholar
• Hallaji NA, Rao PP, Trope GE. Preservative content in generic and brand name glaucoma eye drops. Can J Ophthalmol 2016; 51: 492.
   Web of Science ®Google Scholar
• Newman AR, Andrew NH. Changes in Australian practice patterns for glaucoma management. Clin Exp Ophthalmol 2019; 47: 571–580.
   Web of Science ®Google Scholar
• Kerr NM, Kumar HK, Crowston JG et al. Glaucoma laser and surgical procedure rates in Australia. Br J Ophthalmol 2016; 100: 1686–1691.
   Web of Science ®Google Scholar
• Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial. I. Acute effects of argon laser trabeculoplasty on intraocular pressure. Arch Ophthalmol 1989; 107: 1135–1142.
   Google Scholar
• Bergea B. Repeated argon laser trabeculoplasty. Acta Ophthalmol (Copenh) 1986; 64: 246–250.
   Web of Science ®Google Scholar
• Feldman RM, Katz LJ, Spaeth GL et al. Long‐term efficacy of repeat argon laser trabeculoplasty. Ophthalmology 1991; 98: 1061–1065.
   Web of Science ®Google Scholar
• Fink AI, Jordan AJ, Lao PN et al. Therapeutic limitations of argon laser trabeculoplasty. Br J Ophthalmol 1988; 72: 263–269.
   Web of Science ®Google Scholar
• Grayson DK, Camras CB, Podos SM et al. Long‐term reduction of intraocular pressure after repeat argon laser trabeculoplasty. Am J Ophthalmol 1988; 106: 312–321.
   Web of Science ®Google Scholar
• Thomas JV, Simmons RJ, Belcher CD III. Argon laser trabeculoplasty in the presurgical glaucoma patient. Ophthalmology 1982; 89: 187–197.
   Web of Science ®Google Scholar
• Brubaker RF, Liesegang TJ. Effect of trabecular photocoagulation on the aqueous humor dynamics of the human eye. Am J Ophthalmol 1983; 96: 139–147.
   Web of Science ®Google Scholar
• Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res 1995; 60: 359–371.
   Web of Science ®Google Scholar
• Prasad N, Murthy S, Dagianis JJ et al. A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open angle glaucoma and ocular hypertension. J Glaucoma 2009; 18: 157–160.
   Web of Science ®Google Scholar
• Nagar M, Luhishi E, Shah N. Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty. Br J Ophthalmol 2009; 93: 497–501.
   Web of Science ®Google Scholar
• Bradley JM, Anderssohn AM, Colvis CM et al. Mediation of laser trabeculoplasty‐induced matrix metalloproteinase expression by IL‐1beta and TNFalpha. Invest Ophthalmol Vis Sci 2000; 41: 422–430.
   Web of Science ®Google Scholar
• Izzotti A, Longobardi M, Cartiglia C et al. Trabecular meshwork gene expression after selective laser trabeculoplasty. PLoS One 2011; 6: e20110.
   Web of Science ®Google Scholar
• Garg A, Vickerstaff V, Nathwani N et al. Primary selective laser trabeculoplasty for open‐angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in Glaucoma and Ocular Hypertension trial. Ophthalmology 2019; 126: 1238–1248.
   Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway‐heath D et al. Selective laser trabeculoplasty versus eye drops for first‐line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 2019; 393: 1505–1516.
   Web of Science ®Google Scholar
• Mcilraith I, Strasfeld M, Colev G et al. Selective laser trabeculoplasty as initial and adjunctive treatment for open‐angle glaucoma. J Glaucoma 2006; 15: 124–130.
   Web of Science ®Google Scholar
• Nagar M, Ogunyomade A, O'brart DP et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol 2005; 89: 1413–1417.
   Web of Science ®Google Scholar
• Realini T. Selective laser trabeculoplasty for the management of open‐angle glaucoma in St. Lucia. JAMA Ophthalmol 2013; 131: 321–327.
   Web of Science ®Google Scholar
• Katz LJ, Steinmann WC, Kabir A et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma 2012; 21: 460–468.
   Web of Science ®Google Scholar
• Cho HK, Kee C. Population‐based glaucoma prevalence studies in Asians. Surv Ophthalmol 2014; 59: 434–447.
   Web of Science ®Google Scholar
• Song J, Lee PP, Epstein DL et al. High failure rate associated with 180 degrees selective laser trabeculoplasty. J Glaucoma 2005; 14: 400–408.
   Web of Science ®Google Scholar
• Shibata M, Sugiyama T, Ishida O et al. Clinical results of selective laser trabeculoplasty in open‐angle glaucoma in Japanese eyes: comparison of 180 degree with 360 degree SLT. J Glaucoma 2012; 21: 17–21.
   Web of Science ®Google Scholar
• Ang GS, Fenwick EK, Constantinou M et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. Br J Ophthalmol 2020; 104: 813–821.
   Web of Science ®Google Scholar
• Woo DM, Healey PR, Graham SL et al. Intraocular pressure‐lowering medications and long‐term outcomes of selective laser trabeculoplasty. Clin Exp Ophthalmol 2015; 43: 320–327.
   Web of Science ®Google Scholar
• Weinand FS, Althen F. Long‐term clinical results of selective laser trabeculoplasty in the treatment of primary open angle glaucoma. Eur J Ophthalmol 2006; 16: 100–104.
   Web of Science ®Google Scholar
• Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology 2001; 108: 773–779.
   Web of Science ®Google Scholar
• Soohoo JR, Seibold LK, Ammar DA et al. Ultrastructural changes in human trabecular meshwork tissue after laser Trabeculoplasty. J Ophthalmol 2015; 2015: 476138.
   Web of Science ®Google Scholar
• Cvenkel B, Hvala A, Drnovsek‐olup B et al. Acute ultrastructural changes of the trabecular meshwork after selective laser trabeculoplasty and low power argon laser trabeculoplasty. Lasers Surg Med 2003; 33: 204–208.
   Web of Science ®Google Scholar
• Clement CI. Initial treatment: prostaglandin analog or selective laser Trabeculoplasty. J Curr Glaucoma Pract 2012; 6: 99–103.
   Google Scholar
• Zhao PY, Rahmathullah R, Stagg BC et al. A worldwide price comparison of Glaucoma medications, laser trabeculoplasty, and trabeculectomy surgery. JAMA Ophthalmol 2018; 136: 1271–1279.
   Web of Science ®Google Scholar
• Stein JD, Kim DD, Peck WW et al. Cost‐effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open‐angle glaucoma. Arch Ophthalmol 2012; 130: 497–505.
   Google Scholar
• Chi SC, Kang YN, Hwang DK et al. Selective laser trabeculoplasty versus medication for open‐angle glaucoma: systematic review and meta‐analysis of randomised clinical trials. Br J Ophthalmol 2020. https://doi.org/10.1136/bjophthalmol-2019-315613.
   Web of Science ®Google Scholar
• Camras CB, Alm A, Watson P et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study groups. Ophthalmology 1996; 103: 1916–1924.
   Web of Science ®Google Scholar
• Thomas R, Parikh R, Sood D et al. Efficacy and safety of latanoprost for glaucoma treatment: a three‐month multicentric study in India. Indian J Ophthalmol 2005; 53: 23–30.
   Google Scholar
• Lee JW, Liu CC, Chan JC et al. Predictors of success in selective laser trabeculoplasty for chinese open‐angle glaucoma. J Glaucoma 2014; 23: 321–325.
   Web of Science ®Google Scholar
• Birt CM, Buys YM, Ahmed II et al. Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). J Glaucoma 2010; 19: 460–467.
   Web of Science ®Google Scholar
• Winfield AJ, Jessiman D, Williams A et al. A study of the causes of non‐compliance by patients prescribed eyedrops. Br J Ophthalmol 1990; 74: 477–480.
   Web of Science ®Google Scholar
• Yochim BP, Mueller AE, Kane KD et al. Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. J Glaucoma 2012; 21: 250–254.
   Web of Science ®Google Scholar
• Zwierko T, Jedziniak W, Lesiakowski P et al. Eye‐hand coordination impairment in glaucoma patients. Int J Environ Res Public Health 2019; 16: 1–11.
   Web of Science ®Google Scholar
• Broadway DC, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with Glaucoma. Drugs Aging 2015; 32: 569–581.
   Web of Science ®Google Scholar
• Olthoff CM, Hoevenaars JG, van den Borne BW et al. Prevalence and determinants of non‐adherence to topical hypotensive treatment in Dutch glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2009; 247: 235–243.
   Web of Science ®Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 2009; 116: S30–S36.
   Web of Science ®Google Scholar
• Muller L, Jensen BP, Bachmann LM et al. New technique to reduce systemic side effects of timolol eye drops: the tissue press method‐cross‐over clinical trial. Clin Exp Ophthalmol 2020; 48: 24–30.
   Web of Science ®Google Scholar
• Kaila T, Huupponen R, Salminen L. Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects. J Ocul Pharmacol 1986; 2: 365–369.
   Google Scholar
• Stewart WC, Castelli WP. Systemic side effects of topical beta‐adrenergic blockers. Clin Cardiol 1996; 19: 691–697.
   Web of Science ®Google Scholar
• Kaiserman I, Fendyur A, Vinker S. Topical beta blockers in asthmatic patients‐is it safe? Curr Eye Res 2009; 34: 517–522.
   Web of Science ®Google Scholar
• Brooks TW, Creekmore FM, Young DC et al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta‐blockers. Pharmacotherapy 2007; 27: 684–690.
   Google Scholar
• Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000; 84: 710–713.
   Web of Science ®Google Scholar
• Ergin A, Ornek K, Gullu R et al. Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma. J Ocul Pharmacol Ther 2009; 25: 463–466.
   Web of Science ®Google Scholar
• Snape JP, Waldock A. Spirometry for patients prescribed topical beta‐blockers. Nurs Stand 2000; 15: 35–38.
   Google Scholar
• Maenpaa J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf 2016; 15: 1549–1561.
   Web of Science ®Google Scholar
• Umetsuki MH, Kotegawa T, Nakamura K et al. Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men. J Clin Pharmacol 1997; 37: 58–63.
   Web of Science ®Google Scholar
• Cimolai N. Neuropsychiatric adverse events from topical ophthalmic timolol. Clin Med Res 2019; 17: 90–96.
   Web of Science ®Google Scholar
• Simmons ST, Earl ML, Alphagan/Xalatan Study G. Three‐month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta‐blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002; 109: 307–314.
   Web of Science ®Google Scholar
• Fraunfelder FT, Meyer SM. Sexual dysfunction secondary to topical ophthalmic timolol. JAMA 1985; 253: 3092–3093.
   Web of Science ®Google Scholar
• Katz IM. Sexual dysfunction and ocular timolol. JAMA 1986; 255: 37–38.
   Web of Science ®Google Scholar
• Doyle WJ, Weber PA, Meeks RH. Effect of topical timolol maleate on exercise performance. Arch Ophthalmol 1984; 102: 1517–1518.
   Google Scholar
• Diggory P, Cassels‐brown A, Vail A et al. Avoiding unsuspected respiratory side‐effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345: 1604–1606.
   Web of Science ®Google Scholar
• Moon HS, Ahn B, Lee JH et al. Rejuvenation of the deep superior sulcus in the eyelid. J Cosmet Dermatol 2016; 15: 458–468.
   Web of Science ®Google Scholar
• Maniglia JJ, Maniglia RF, Jorge dos santos MC et al. Surgical treatment of the sunken upper eyelid. Arch Facial Plast Surg 2006; 8: 269–272.
   Google Scholar
• Glaser DA, Jones D, Carruthers J et al. Epidemiologic analysis of change in eyelash characteristics with increasing age in a population of healthy women. Dermatol Surg 2014; 40: 1208–1213.
   Web of Science ®Google Scholar
• Jones D. Enhanced eyelashes: prescription and over‐the‐counter options. Aesthetic Plast Surg 2011; 35: 116–121.
   Web of Science ®Google Scholar
• Ortiz‐perez S, Olver JM. Hypertrichosis of the upper cheek area associated with travoprost treatment of glaucoma. Ophthalmic Plast Reconstr Surg 2010; 26: 376–377.
   Web of Science ®Google Scholar
• Hart J, Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol 2004; 137: 756–757.
   Web of Science ®Google Scholar
• Ozyurt S, Cetinkaya GS. Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost. Actas Dermosifiliogr 2015; 106: 74–75.
   Web of Science ®Google Scholar
• Chen CS, Wells J, Craig JE. Topical prostaglandin F(2alpha) analog induced poliosis. Am J Ophthalmol 2004; 137: 965–966.
   Web of Science ®Google Scholar
• Shaikh MY, Bodla AA. Hypertrichosis of the eyelashes from prostaglandin analog use: a blessing or a bother to the patient? J Ocul Pharmacol Ther 2006; 22: 76–77.
   Web of Science ®Google Scholar
• Tehrani S. Gender difference in the pathophysiology and treatment of glaucoma. Curr Eye Res 2015; 40: 191–200.
   Web of Science ®Google Scholar
• Wilke K. Episcleral venous pressure and pregnancy (proceedings). Acta Ophthalmol Suppl 1975: 40–41.
   Google Scholar
• Strelow B, Fleischman D. Glaucoma in pregnancy: an update. Curr Opin Ophthalmol 2020; 31: 114–122.
   Web of Science ®Google Scholar
• Pellegrino M, D'oria L, De luca C et al. Glaucoma drug therapy in pregnancy: literature review and teratology information service (TIS) case series. Curr Drug Saf 2018; 13: 3–11.
   Web of Science ®Google Scholar
• Qureshi IA. Intraocular pressure and pregnancy: a comparison between normal and ocular hypertensive subjects. Arch Med Res 1997; 28: 397–400.
   Web of Science ®Google Scholar
• Chiba T, Kashiwagi K, Ishijima K et al. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol 2004; 48: 141–147.
   Web of Science ®Google Scholar
• Carruthers J, Carruthers A. Social significance of the eyebrows and periorbital complex. J Drugs Dermatol 2014; 13: s7–s11.
   Web of Science ®Google Scholar
• Cartwright MJ, Kurumety UR, Nelson CC et al. Measurements of upper eyelid and eyebrow dimensions in healthy white individuals. Am J Ophthalmol 1994; 117: 231–234.
   Web of Science ®Google Scholar
• Kantarci FA, Kantarci MN, Bilgi S. Age estimation using level of eyebrow and eyelash whitening. Med Sci Monit 2014; 20: 97–102.
   Web of Science ®Google Scholar
• Draelos ZD. Special considerations in eye cosmetics. Clin Dermatol 2001; 19: 424–430.
   Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven‐year results. Ophthalmology 1998; 105: 1146–1164.
   Web of Science ®Google Scholar
• Ederer F, Gaasterland DA, Dally LG et al. Comparison of treatment outcomes within race: 10‐year results. Ophthalmology 2004; 111: 651–664.
   Web of Science ®Google Scholar
• Varma R. Trabeculoplasty, trabeculectomy, and race: is there a difference in response to treatment between blacks and whites? Ophthalmology 1998; 105: 1135–1136.
   Web of Science ®Google Scholar
• Ghosh C. Glaucoma treatment outcomes. Ophthalmology 2004; 111: 1943.
   Web of Science ®Google Scholar
• Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time‐course of latanoprost‐induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997; 41: S129–S138.
   Web of Science ®Google Scholar
• Chou SY, Chou CK, Kuang TM et al. Incidence and severity of iris pigmentation on latanoprost‐treated glaucoma eyes. Eye (Lond) 2005; 19: 784–787.
   Web of Science ®Google Scholar
• Lavia C, Dallorto L, Maule M et al. Minimally‐invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta‐analysis. PLoS One 2017; 12: e0183142.
   Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW et al. Interim clinical outcomes in the collaborative initial Glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943–1953.
   Web of Science ®Google Scholar
• Migdal C, Gregory W, Hitchings R. Long‐term functional outcome after early surgery compared with laser and medicine in open‐angle glaucoma. Ophthalmology 1994; 101: 1651–1656.
   Web of Science ®Google Scholar
• Anand A, Negi S, Khokhar S et al. Role of early trabeculectomy in primary open‐angle glaucoma in the developing world. Eye (Lond) 2007; 21: 40–45.
   Web of Science ®Google Scholar
• Dastiridou AI, Katsanos A, Denis P et al. Cyclodestructive procedures in Glaucoma: a review of current and emerging options. Adv Ther 2018; 35: 2103–2127.
   Web of Science ®Google Scholar
• Pastor SA, Singh K, Lee DA et al. Cyclophotocoagulation: a report by the American Academy of ophthalmology. Ophthalmology 2001; 108: 2130–2138.
   Web of Science ®Google Scholar
• Egbert PR, Fiadoyor S, Budenz DL et al. Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open‐angle glaucoma. Arch Ophthalmol 2001; 119: 345–350.
   Google Scholar